Article
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients: Pooled Results From the Phase 3 Double-Blind Randomized ECHO and THRIVE Trials
Fecha
2012Registro en:
COHEN, C. J. et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. Journal of Acquired Immune Deficiency Syndromes, v. 60, n. 1, p. 33-42, 2012.
1525-4135
10.1097/QAI.0b013e31824d006e
Autor
Cohen, Calvin J.
Molina, Jean-Michel
Cahn, Pedro
Clotet, Bonaventura
Fourie, Jan
Grinsztejn, Beatriz
Wu, Hao
Johnson, Margaret A.
Saag, Michael
Supparatpinyo, Khuanchai
Crauwels, Herta
Lefebvre, Eric
Rimsky, Laurence T.
Vanveggel, Simon
Williams, Peter
Boven, Katia
ECHO Study Group
THRIVE Study Group